In contrast, the use of RNAi, EGCG, or sulfasalazine to inhibit the genetic and pharmacological properties of the HSPA5–GPX4 pathway enhanced gemcitabine sensitivity in PDAC cells in vitro and mouse pancreatic cancer animal models [125]. The gene discussed is GPX4; the disease is pancreatic neoplasm.